Synairgen plc Exercise of Options and Total Voting Rights (2615C)
October 15 2020 - 12:35PM
UK Regulatory
TIDMSNG
RNS Number : 2615C
Synairgen plc
15 October 2020
Synairgen plc
("Synairgen" or the "Company")
Exercise of Options and Total Voting Rights
Southampton, UK - 15 October 2020: Synairgen plc (LSE: SNG), the
respiratory drug discovery and development company, announces that
the Company has applied for a total of 177,300 new ordinary shares
of 1 pence each in the Company ("Ordinary Shares") to be issued and
allotted pursuant to the exercise of options by Jody Brookes, PDMR,
and certain other employees of the Company.
Of these new Ordinary Shares, 141,702 were exercised at a price
of 1 pence by Jody Brookes and subsequent to this, the Company was
notified on 15 October that on that same day, Jody Brookes sold the
141,702 Ordinary Shares at a price of 198.327 pence per Ordinary
Share.
As a result of the exercise of options, application has been
made for the 177,300 new Ordinary Shares to be admitted to trading
on AIM ("Admission") and it is expected that Admission will become
effective and trading will commence at 8.00 a.m. on or around 21
October 2020.
The new Ordinary Shares will rank pari passu with the existing
shares of the Company. Following Admission, the Company's issued
share capital will consist of 165,088,214 Ordinary Shares.
Accordingly, the figure of 165,088,214 may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in the Company under the FCA's Disclosure
Guidance and Transparency Rules.
Enquiries:
Synairgen plc +44 (0) 23 8051 2800
Richard Marsden (Chief Executive Officer)
John Ward (Finance Director)
finnCap - Nominated Adviser and Joint Broker +44 (0) 20 7220
0500
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate
Finance)
Alice Lane / Sunila de Silva (ECM)
Numis - Joint Broker +44 (0) 20 7260 1000
James Black / Freddie Barnfield / Duncan Monteith
Consilium Strategic Communications - Financial Media and
Investor +44 (0) 20 3709 5700
Relations Adviser
Mary-Jane Elliott / Sue Stuart / Olivia Manser
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Sir Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on lung viral defence in asthma, COPD and COVID-19, uses
its differentiating human biology BioBank platform and
world-renowned international academic KOL network to discover and
develop novel therapies for respiratory disease. Synairgen is
quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com
1. Details of Persons Discharging Managerial Responsibilities ('PDMR')
/ person closely associated with them ('PCA')
a) Name Jody Brookes
2. Reason for notification
a) Position / status Head of Clinical Operations, PDMR of the
Company
b) Initial notification Initial Notification
/ amendment
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Synairgen plc
b) LEI 213800IMMTOPPDF8HD24
4. Details of the transaction(s):
a) Description of the financial O ptions over o rdinary shares of 1p each
instrument
Identification code GB00B0381Z20
b) Nature of the transaction Exercise of options over Ordinary Shares;
and
Sale of Ordinary Shares of 1p each
c) Price(s) and volume(s) Price Volume
Exercise
of Options 1p 141,702
--------- --------
Sale of
Ordinary
Shares 198.327p 141,702
--------- --------
d) Aggregated information n/a
Aggregated volume Price
e) Date of the transaction 15 October 2020
f) Place of the transaction London Stock Exchange
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBLBDGGXBDGGU
(END) Dow Jones Newswires
October 15, 2020 12:35 ET (16:35 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2023 to Apr 2024